Elo Mutual Pension Insurance Co increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 17.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,860 shares of the medical research company's stock after buying an additional 2,777 shares during the period. Elo Mutual Pension Insurance Co's holdings in IQVIA were worth $3,706,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of IQV. Smith Group Asset Management LLC acquired a new stake in shares of IQVIA in the 4th quarter valued at approximately $1,616,000. Nordea Investment Management AB raised its holdings in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after purchasing an additional 452,029 shares during the period. Hickory Asset Management Inc. bought a new position in shares of IQVIA during the fourth quarter worth $941,000. Fifth Third Bancorp grew its holdings in shares of IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock valued at $2,590,000 after buying an additional 1,521 shares during the period. Finally, Graphene Investments SAS increased its position in shares of IQVIA by 22.0% in the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock valued at $2,948,000 after buying an additional 2,700 shares in the last quarter. 89.62% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several brokerages have issued reports on IQV. Citigroup lowered their price target on IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Royal Bank of Canada restated an "outperform" rating and set a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. Robert W. Baird reduced their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, January 21st. Bank of America cut their price objective on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a research report on Friday, December 13th. Finally, Stephens began coverage on IQVIA in a report on Friday, December 20th. They set an "overweight" rating and a $250.00 target price for the company. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and a consensus target price of $249.05.
View Our Latest Report on IQVIA
IQVIA Price Performance
Shares of IQV stock traded down $1.12 during trading hours on Monday, reaching $176.28. The company's stock had a trading volume of 2,234,715 shares, compared to its average volume of 1,303,021. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a fifty-two week low of $169.54 and a fifty-two week high of $253.84. The company has a market capitalization of $31.08 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 1.99 and a beta of 1.50. The firm's 50 day simple moving average is $193.15 and its 200-day simple moving average is $206.05.
IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
